• Home
  • NEW DAY MEDICINE
  • 2 (34/1) 2021
  • 37 -2 (34/1) 2021 — Ochilova G.S., Musayeva D.M. — THE PATIENT’S GENOTYPE IS THE MAIN INDICATOR FOR CHOOSING AN EFFECTIVE AND SAFE PHARMACOTHERAPY FOR CHRONIC GASTRITIS

37 -2 (34/1) 2021 — Ochilova G.S., Musayeva D.M. — THE PATIENT’S GENOTYPE IS THE MAIN INDICATOR FOR CHOOSING AN EFFECTIVE AND SAFE PHARMACOTHERAPY FOR CHRONIC GASTRITIS

THE PATIENT’S GENOTYPE IS THE MAIN INDICATOR FOR CHOOSING AN EFFECTIVE AND SAFE PHARMACOTHERAPY FOR CHRONIC GASTRITIS

Ochilova G.S., Bukhara State Medical Institute named after Abu Ali ibn Sino

Musayeva D.M. Bukhara State Medical Institute named after Abu Ali ibn Sino

Resume,

The article presents the results of a genotypic study of patients with chronic gastritis in the Bukhara region by the polymorphism rs1045642 of the MDR-1 gene by the polymorphic marker C3435T. It turned out that in the present region, patients with the CT genotype prevail and the type B of chronic gastritis prevails in terms of occurrence. When studying the effectiveness of the classical pharmacotherapy used, depending on the genotype of a patient with HCG, the disease ends with recovery mainly in patients with the SS genotype.

Key words: MDR-1 gene, polymorphism, chronic gastritis, polymorphic marker C3435T of MDR-1 gene, P-glycoprotein.

First page

200

Last page

205

For citation: Ochilova G.S., Musayeva D.M. The patient’s genotype is the main indicator for choosing an effective and safe pharmacotherapy for chronic gastritis //New Day in Medicine 2(34/1)2021 200-205 https://cutt.ly/YbDHEcR

LIST OF REFERENCES

  1. Borst P. Genetic mechanisms of drug resistance. A review // Acta Oncol. 1991. Vol. 30. P. 87-101.
  2. Chubarova S.V., Kraposhina A.Yu., Sobko Ye.A., Demko I.V., Salmina A.B. Fiziologicheskiye i klinicheskiye aspekty R-glikoproteina // Byulleten’. Vyp.45. – 2012 g. 91-97 s.
  3. Grishina VB, Sychev DA, Borzova EY et al. The effect of polymorphic genetic markers CYP2С19 (rs4244285 and rs4986893), CYP2D6 (rs3892097), ABCB1 (rs1045642) on sedation during treatment with histamine H1-receptor antagonist. Klinicheskaya farmakologiya i terapiya = Clin Pharmacol Ther 2020; 29(2):68-72 (In Russ.). DOI 10.32756/ 0869-5490-2020-2-68-72.
  4. Kim R. Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab. Rev., 2012, 34, 47-54.
  5. Kitayeva Ye.Yu., Shprakh V.V., Mirzayev K. B., Ryzhikova K.A., Shuyev G. N., Sozayeva ZH. A., Pimenova YU. A., Kogay V.V., Sychev D.A. // Chastota polimorfizmov genov CYP2C19 i ABCB1, assotsiirovannykh s izmeneniyem antiagregantnogo deystviya klopidogrela, u russkikh i buryat. Sibirskoye meditsinskoye obozreniye. 2018 №3 43-50 S.
  6. Klichova F.K., Ochilova G.S. Znacheniye gena MDR-1 farmakoterapii. Sbornik tezisov II Vserossiyskoy nauchno- prakticheskoy konferentsii s mezhdunarodnym uchastiyem.Bezopasnost’ farmakoterapii: NOLI NOCERE! g.Kazan, 16 maya 2019 g.
  7. Kukes V.G. Metabolizm lekarstvennykh sredstv: kliniko-farmakologicheskiye aspekty. – M.: Reafarm, 2004. – S. 113-120.
  8. Kuzuya T., Kobayashi T., Moriyama N.,Nagasaka T., Yokoyama I., Uchida K., Nakao A., Nabeshima T. Amlodipine, but not MDR1polymorphisms, alters the pharmacokinetics of cyclosporine A in Japanese kidney transplant recipients//Transplantation. 2003. Vol.76, №5.P. 865–868.
  9. Musayeva D.M., Ochilov A.K., Ochilova G.S. Korrektsiya farmakometaboliziruyushchey funktsii pecheni antioksidantami //Dostizheniya nauki i obrazovaniya. – 2018. – №. 10 (32).
  10. Musayeva D.M., Ochilova G.S. Surunkali gastritni davolashda MDR-1 allel variantlarining akamiyati //Materialy mezhdunarodnoy nauchno-prakticheskoy onlayn-konferentsii” Aktual’nyye voprosy meditsinskoy nauki v XXI veke” g. Tashkent. – 2019. – T. 25.
  11. Muslimova O.V., Sychev D.A., Shikh Ye.V., Kozakov R.Ye. Polimorfizm gena MDR1 i risk razvitiya ostrogo infarkta miokarda u bol’nykh IBS // Biomeditsina. 2011. №4. URL: https://cyberleninka.ru/article/n/polimorfizm-gena-mdr1-i-risk-razvitiya-ostrogo-infarkta-miokarda-u-bolnyh-ibs (data obrashcheniya: 10.05.2021).
  12. Musayeva D.M., Ochilova G.S. “Znacheniye gena MDR-1 v farmakoterapii pri khronicheskikh gastritakh» // Problemy biologii i meditsiny – 2019. – № 4 (113).
  13. Ochilov A.K., Musayeva D.M. lecheniye khronicheskogo gastrita v zavisimosti ot allel’nykh variantov gena CYP2C19 //dlya provedeniya I-mezhdunarodnoy nauchno-prakticheskoy onlayn-konferentsii «Aktual’nyye voprosy meditsinskoy nauki v XXI veke». – 2019. – S. 267.
  14. Ochilova G. S., Musayeva D. M. Vliyaniye polimarfizma gena MDR-1 na effektivnost’ lecheniya khronicheskogo gastrita //New day medicine. – 2020. – T. 1. – №. 29. – S. 2020. 309-312.
  15. Ochilova D.A., Rakhmonkulova N.G., Effectiveness of combination therapy in the treatment of hypertensive disease//New Day in Medicine 1(29)2020 305-307 https://cutt.ly/hvNY7VE
  16. Ochilov А.К, Musaeva D.M., Features of cyp2c19 gene for individualized pharmacotherapy//New Day in Medicine 1(29)2020 62-65 https://cutt.ly/JbSmwZ4
  17. Ochilova G.S. Kharakteristika glikoproteina-R kak belka transportera lekarstvennykh veshchestv  // New Day in Medicine – 2020. – №2 (30/2). – S. 60-63.
  18. Saliyeva M. KH., Azizov YU. D., Mirzayeva M. M. Puti modernizatsii mediko-sanitarnoy pomoshchi sel’skomu naseleniyu //Re-health journal. – 2019. – №.2.
  19. Saliyeva M. KH. i dr. Ob uluchshenii mediko-sanitarnoy pomoshchi //Dostizheniya nauki i obrazovaniya. – 2018. – №. 12 (34).
  20. Sychev D.A., Ramenskaya G.V., Ignat’yev I.V., Kukes V.G. Klinicheskaya farmakogenetika /Pod redaktsiyey Kukesa V.G., Bochkova N.P. M.: Geotar-Media, 2007. 248 s.
 

file

download